多发性硬化儿童初次使用芬戈莫德治疗的病例分析  

Case report of the initial fingolimod therapy in children with multiple sclerosis

作　　者：魏然 董秀 陈超阳[1] 武元[2] 周颖[1,4] 吴晔[2] 崔一民[1,3,4] WEI Ran;DONG Xiu;CHEN Chao-yang;WU Yuan;ZHOU Ying;WU Ye;CUI Yi-min(Department of Pharmacy,Peking University First Hospital,Beijing 100034,China;Department of Pediatrics,Peking University First Hospital,Beijing 100034,China;Institute of Clinical Pharmacology,Peking University First Hospital,Beijing 100034,China;Department f Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Science,Peking University,Beijing 100191,China)

机构地区：[1]北京大学第一医院药学部,北京100034 [2]北京大学第一医院儿科,北京100034 [3]北京大学第一医院临床药理研究所,北京100034 [4]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《中国临床药理学杂志》2023年第23期3475-3478,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家科技重大专项-重大新药创制基金资助项目(2017ZX09304029-006-001)。

摘　　要：本文通过病例系列报告,对4例首次接受芬戈莫德治疗的多发性硬化(MS)儿童病例进行分析,包括1例9岁、50 kg的女童,基础心率低,用药后发展为无症状的心动过缓;另外3例患儿未出现心脏相关药物不良反应,并评价首次使用芬戈莫德治疗的MS儿童的心脏安全性,建议对基础心率缓慢、年龄小、体质量低的儿童加强监测。为保证使用芬戈莫德的安全性,可适当延长对于心脏的监测时间,并重点加强夜间监测。A case series report was conducted to analyze the cases of children with multiple sclerosis(MS)who received fingolimod for the first time.Four Chinese children with MS were reported.A 9-year-old girl weighted 50 kg with low basal heart rate developed asymptomatic bradycardia.The other 3 children did not experience cardiac adverse reactions.Cardiac safety of the first dose of fingolimod in children with MS was also evaluated.We suggest that special attention should be paid to patients with slow basal heart rate,young age and low body weight.In order to promote its safe use at initiation,the monitoring time can be extended appropriately and night monitoring can be strengthened.

关 键 词：芬戈莫德 多发性硬化 心脏毒性 儿童 

分 类 号：R97[医药卫生—药品]